Skip to Content

Turvel IV

Active Substance: alatrofloxacin mesylate
Common Name: trovafloxacin
ATC Code: J01MA13
Marketing Authorisation Holder: Pfizer Limited
Active Substance: alatrofloxacin mesylate
Status: Withdrawn
Authorisation Date: 1998-07-03
Therapeutic Area: Bacterial Infections
Pharmacotherapeutic Group: Antibacterials for systemic use

Therapeutic Indication

Trovafloxacin is a synthetic broad spectrum quinolone antibacterial agent indicated for the treatment of the following infections in adults:

  • Pneumonia: Community Acquired Pneumonia and Nosocomial Pneumonia (mild, moderate, and severe).

Note: Efficacy in patients with very severe nosocomial pneumonia and in particular infections due to less susceptible pathogens e.g. P. aeruginosa, has not been established. See also section 4.2.

  • Acute Exacerbations of Chronic Bronchitis
  • Acute Sinusitis
  • Complicated Intra-abdominal Infections and Acute Pelvic Infections
  • Salpingitis
  • Uncomplicated Gonococcal Urethritis and Cervicitis
  • Chlamydial Cervicitis
  • Complicated Skin and Soft Tissue Infections

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

The marketing authorisation for Turvel IV has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.